Aoxing Pharmaceutical Competitors

American Bio Medica (OTCMKTS:ABMC) and Aoxing Pharmaceutical (OTCMKTS:AOXG) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Valuation & Earnings

This table compares American Bio Medica and Aoxing Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

Aoxing Pharmaceutical has lower revenue, but higher earnings than American Bio Medica.

Profitability

This table compares American Bio Medica and Aoxing Pharmaceutical's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings and target prices for American Bio Medica and Aoxing Pharmaceutical, as reported by MarketBeat.

Volatility & Risk

American Bio Medica has a beta of -1.45, suggesting that its share price is 245% less volatile than the S&P 500. Comparatively, Aoxing Pharmaceutical has a beta of 3.26, suggesting that its share price is 226% more volatile than the S&P 500.

Summary

Aoxing Pharmaceutical beats American Bio Medica on 3 of the 4 factors compared between the two stocks.

Aoxing Pharmaceutical (OTCMKTS:AOXG) and Amarantus BioScience (OTCMKTS:AMBS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Insider and Institutional Ownership

0.0% of Amarantus BioScience shares are owned by institutional investors. 17.8% of Aoxing Pharmaceutical shares are owned by insiders. Comparatively, 10.3% of Amarantus BioScience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Aoxing Pharmaceutical and Amarantus BioScience's revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of current recommendations for Aoxing Pharmaceutical and Amarantus BioScience, as reported by MarketBeat.

Volatility & Risk

Aoxing Pharmaceutical has a beta of 3.26, indicating that its share price is 226% more volatile than the S&P 500. Comparatively, Amarantus BioScience has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.

Profitability

This table compares Aoxing Pharmaceutical and Amarantus BioScience's net margins, return on equity and return on assets.

Summary

Aoxing Pharmaceutical beats Amarantus BioScience on 2 of the 3 factors compared between the two stocks.

Akorn (OTCMKTS:AKRXQ) and Aoxing Pharmaceutical (OTCMKTS:AOXG) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.

Profitability

This table compares Akorn and Aoxing Pharmaceutical's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Akorn and Aoxing Pharmaceutical, as reported by MarketBeat.com.

Volatility & Risk

Akorn has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Aoxing Pharmaceutical has a beta of 3.26, meaning that its stock price is 226% more volatile than the S&P 500.

Institutional and Insider Ownership

0.1% of Akorn shares are owned by institutional investors. 3.9% of Akorn shares are owned by company insiders. Comparatively, 17.8% of Aoxing Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Akorn and Aoxing Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

Aoxing Pharmaceutical has lower revenue, but higher earnings than Akorn.

Summary

Aoxing Pharmaceutical beats Akorn on 5 of the 7 factors compared between the two stocks.

Aoxing Pharmaceutical (OTCMKTS:AOXG) and VG Life Sciences (OTCMKTS:VGLS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Aoxing Pharmaceutical and VG Life Sciences, as reported by MarketBeat.

Volatility and Risk

Aoxing Pharmaceutical has a beta of 3.26, meaning that its share price is 226% more volatile than the S&P 500. Comparatively, VG Life Sciences has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.

Valuation & Earnings

This table compares Aoxing Pharmaceutical and VG Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Aoxing Pharmaceutical and VG Life Sciences' net margins, return on equity and return on assets.

Summary

Aoxing Pharmaceutical beats VG Life Sciences on 1 of the 1 factors compared between the two stocks.

Innovus Pharmaceuticals (OTCMKTS:INNVD) and Aoxing Pharmaceutical (OTCMKTS:AOXG) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Profitability

This table compares Innovus Pharmaceuticals and Aoxing Pharmaceutical's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Innovus Pharmaceuticals and Aoxing Pharmaceutical's top-line revenue, earnings per share and valuation.

Aoxing Pharmaceutical has lower revenue, but higher earnings than Innovus Pharmaceuticals.

Insider and Institutional Ownership

10.4% of Innovus Pharmaceuticals shares are held by institutional investors. 16.4% of Innovus Pharmaceuticals shares are held by company insiders. Comparatively, 17.8% of Aoxing Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Innovus Pharmaceuticals has a beta of 2.89, meaning that its stock price is 189% more volatile than the S&P 500. Comparatively, Aoxing Pharmaceutical has a beta of 3.26, meaning that its stock price is 226% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Innovus Pharmaceuticals and Aoxing Pharmaceutical, as reported by MarketBeat.com.

Summary

Aoxing Pharmaceutical beats Innovus Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

Aoxing Pharmaceutical (OTCMKTS:AOXG) and Immune Pharmaceuticals (OTCMKTS:IMNPQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Risk & Volatility

Aoxing Pharmaceutical has a beta of 3.26, suggesting that its share price is 226% more volatile than the S&P 500. Comparatively, Immune Pharmaceuticals has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.

Valuation & Earnings

This table compares Aoxing Pharmaceutical and Immune Pharmaceuticals' top-line revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of recent recommendations for Aoxing Pharmaceutical and Immune Pharmaceuticals, as provided by MarketBeat.

Profitability

This table compares Aoxing Pharmaceutical and Immune Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Aoxing Pharmaceutical beats Immune Pharmaceuticals on 1 of the 1 factors compared between the two stocks.